Fundamental Analysis Stories

China Automotive EBITDA Margin is relatively stable at the moment as compared to the past year. China Automotive reported last year EBITDA Margin of 0.045. As of 03/30/2022, Enterprise Value over EBITDA is likely to grow to 7.36, while Earnings before Tax are likely to drop (2.6 M). China Automotive Sys is scheduled to announce its earnings today. The next earnings report is expected on the 11th of May 2022. While some of us are excited about consumer cyclical space, let's try to sum up China Automotive Sys in greater detail to make a better evaluation of its fundamental indicators. We will evaluate why we are still confident in anticipation of a recovery. China Automotive Sys chance of distress is under 45 percent. Will China Automotive retail investors continue to acquire in April?
  over six months ago at Macroaxis 
By Raphi Shpitalnik
Raphi Shpitalnik
Ionq Inc is scheduled to announce its earnings tomorrow. While some of us are excited about technology space, let's try to recap Ionq Inc in greater detail to make a better evaluation of its fundamental indicators. What exactly are Ionq shareholders getting in April? Will insiders continue to hold, or should we expect a sell-off?
  over six months ago at Macroaxis 
By Vlad Skutelnik
Vlad Skutelnik
In spite of fairly strong basic indicators, Dave Busters is not utilizing all of its potentials. The latest stock price disturbance, may contribute to a short-term swings for the investors. We currently estimate Dave Busters as undervalued. The real value is approaching 45.43 per share.
  over six months ago at Macroaxis 
By Ellen Johnson
Ellen Johnson
Agrify Corp Cost of Revenue is fairly stable at the moment as compared to the past year. Agrify Corp reported Cost of Revenue of 13.24 Million in 2021. Gross Profit is likely to rise to about 707.2 K in 2022, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (19.1 M) in 2022. In spite of fairly strong technical and fundamental indicators, Agrify Corp is not utilizing all of its potentials. The current stock price disturbance, may contribute to a short-term swings for the investors. Agrify Corp probability of distress is under 24 percent. Will Agrify Corp investors continue to trade in April?
  over six months ago at Macroaxis 
By Vlad Skutelnik
Vlad Skutelnik
If you have been keeping an eye on First Watch you know that now may not be the best time to buy. First Watch Restaurant probability of financial unrest is over 58 percent. Will shareholders continue to be optimistic, or should we expect a sell-off in April?
  over six months ago at Macroaxis 
By Gabriel Shpitalnik
Gabriel Shpitalnik
There are many examples of prices slipping after a drastic change in one of the basic indicators. In this short article, we will go over a few of First Advantage's essential fundamentals. We will evaluate why we are still confident in anticipation of a recovery. Will investors continue to hold, or should we expect a sell-off?
  over six months ago at Macroaxis 
By Vlad Skutelnik
Vlad Skutelnik
Imedia Brands Enterprise Value is most likely to decrease significantly in the upcoming years. The preceding year's Enterprise Value was reported at 370.01 Million. The current Invested Capital is estimated to increase to about 170.8 M, while Earnings before Tax are projected to decrease to (603.1 K). Imedia Brands is scheduled to announce its earnings today. The next earnings report is expected on the 24th of May 2022. Is consumer cyclical space attracting new stockholders, let's check if Imedia Brands is sending any bullish signals. The entity responds to the market. We can now examine Imedia as a potential investment option for your portfolios.
  over six months ago at Macroaxis 
By Vlad Skutelnik
Vlad Skutelnik
Augmedix Debt Current is fairly stable at the moment as compared to the past year. Augmedix reported Debt Current of 7.6 Million in 2021. Debt Non Current is likely to rise to about 8.3 M in 2022, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (16.5 M) in 2022. Augmedix is scheduled to announce its earnings today. Although many conservative investors are getting more into healthcare space, we should study Augmedix's current fundamentals in more details. We will cover the possibilities of making Augmedix into a steady grower in April. Will investors continue to hold, or should we expect a sell-off?
  over six months ago at Macroaxis 
By Vlad Skutelnik
Vlad Skutelnik
The stock is undergoing an active upward rally. Technology space may be getting hot again, let's check if Gitlab Inc Cl is sending any bullish signals to investors. We will analyze why Gitlab Inc investors may still consider a stake in the business. We currently estimate Gitlab Inc as undervalued. The real value is approaching 61.84 per share.
  over six months ago at Macroaxis 
By Gabriel Shpitalnik
Gabriel Shpitalnik
Ampio Pharmaceuticals Average Assets are projected to decrease significantly based on the last few years of reporting. The past year's Average Assets were at 13.3 Million. The current year Average Equity is expected to grow to about 13 M, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are forecasted to decline to (18.3 M). One of the important factors of profitable assets selection is to know the future growth potential of an asset before buying its shares. This post will digest Ampio Pharmaceuticals. We will cover the possibilities of making Ampio Pharmaceuticals into a steady grower in April. We currently estimate Ampio Pharmaceuticals as undervalued. The real value is approaching 1.33 per share.
  over six months ago at Macroaxis 
By Raphi Shpitalnik
Raphi Shpitalnik